Please note that the JSE will be closing at 3pm on 26th April
to accommodate for the launch of the new Derivatives platform.

Indivior: $3 bln U.S. fine may reduce - Bernstein

** British drugmaker Indivior's shares up 14.5 pct to 40.3p

** U.S. DoJ indicted Indivior for illegally increasing prescriptions for its opioid addiction treatment Suboxone and demanded at least $3 bln in fines; stock sank ~72 pct on Thursday

** Suboxone Film generated $2.9 bln in total in the investigated years (2010-2014) - This suggests that the $3 bln headline fine is extremely aggressive, and there is potential for it to be reduced: Bernstein

** Bernstein: With respect to timings, precedent cases suggest that a final decision is unlikely to be reached very quickly, given it involves lengthy negotiations between the parties

** In 2012, GSK was fined $3 bln on 3 of its best-selling drugs that together generated more than $25 bln in sales during the years covered by the settlement (Wellbutrin and Paxil from 1999-2003, Avandia from 2001-2007)

** In 2013, J&J was fined $2.2 bln fine for improperly promoting its antipsychotic drug Risperdal between 1999-2005; drug had sales of over $18 bln in the period

** Bernstein expects the final court decision to take up to 2 years before a final verdict is made

** Stock lost over half a billion pounds in market value on Thursday; Indivior, which was valued at 3 bln pounds a year ago, is now valued at 257 mln pounds ($1 = 0.7637 pounds) (Reporting By Justin George Varghese in Bengaluru)

2019-04-15 12:00:33

© 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.